

## Selecta Biosciences to Webcast Presentation at Needham & Company's 14th Annual Healthcare Conference

April 6, 2015 9:39 AM ET

**WATERTOWN, Mass. – April 6, 2015** – Selecta Biosciences, a clinical-stage biotechnology company developing novel drugs that use immune-modulating nanomedicines based on Synthetic Vaccine Particles (SVP™), announced today that Werner Cautreels, PhD, President and CEO, will present a company overview at the Needham & Company's 14th Annual Healthcare Conference on Tuesday, April 14, 2015, at 11:40 am EDT in New York City.

A live webcast of the presentation will be available on the company's website, [www.selectabio.com](http://www.selectabio.com) and [www.wsw.com/webcast/needham71/sel](http://www.wsw.com/webcast/needham71/sel). An archived webcast recording will be available on the Selecta website for approximately 90 days following the conference.

### **About Selecta**

Selecta Biosciences, Inc. is a clinical-stage biotechnology company developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles.

Selecta's immunomodulatory SVPs can induce antigen-specific immune tolerance, enabling them to be applied in a variety of therapeutic areas with large unmet medical need. The company is focused on three key near-term applications: inhibition of immunogenicity of biologic therapies, treatment of allergies, and treatment of autoimmune diseases. Immunogenicity adversely affects the safety and efficacy profile for many biological therapies, and is known to have caused the termination of a number of promising biological therapies in clinical development. Selecta's SVP is a product engine that has the potential to unlock the full therapeutic value of biologic therapies.

SVP immunotherapeutics can activate the body's 'killer' immune cells, known as cytolytic T-lymphocytes (CTL), to selectively attack tumor or chronically infected cells. For Immuno-oncology applications SVP products are capable of being used either alone or in conjunction with other cancer immunotherapies to elicit a focused and durable immune response specifically targeted against tumors. Selecta's initial programs in cancer include cervical, head, neck and other cancers.

Through proprietary products and collaborations with leading pharmaceutical companies and research organizations, Selecta is building a pipeline of product candidates to address unmet medical needs in serious and chronic diseases. Selecta Biosciences, Inc. is based in Watertown, Massachusetts, USA. For more information, please visit [www.selectabio.com](http://www.selectabio.com).

###

### **MEDIA CONTACT:**

Kathryn Morris  
The Yates Network  
+1-845-635-9828  
[kathryn@theyatesnetwork.com](mailto:kathryn@theyatesnetwork.com)

### **INVESTOR CONTACT:**

Stephanie Ascher  
Stern Investor Relations, Inc.  
+1-212-362-1200  
[stephanie@sternir.com](mailto:stephanie@sternir.com)